Cargando…
Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates
Patients receiving treatment with B-cell-depleting monoclonal antibodies, such as anti-CD20 monoclonal antibodies, such as rituximab and obinutuzumab, either for hematological disease or another diagnosis, such as a rheumatological disease, are at an increased risk for medical complications and mort...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059055/ https://www.ncbi.nlm.nih.gov/pubmed/36992465 http://dx.doi.org/10.3390/v15030756 |
_version_ | 1785016783728541696 |
---|---|
author | Ioannou, Petros Katsigiannis, Athanasios Papakitsou, Ioanna Kopidakis, Ioannis Makraki, Eirini Milonas, Dimitris Filippatos, Theodosios D. Sourvinos, George Papadogiannaki, Marina Lydaki, Evaggelia Chamilos, Georgios Kofteridis, Diamantis P. |
author_facet | Ioannou, Petros Katsigiannis, Athanasios Papakitsou, Ioanna Kopidakis, Ioannis Makraki, Eirini Milonas, Dimitris Filippatos, Theodosios D. Sourvinos, George Papadogiannaki, Marina Lydaki, Evaggelia Chamilos, Georgios Kofteridis, Diamantis P. |
author_sort | Ioannou, Petros |
collection | PubMed |
description | Patients receiving treatment with B-cell-depleting monoclonal antibodies, such as anti-CD20 monoclonal antibodies, such as rituximab and obinutuzumab, either for hematological disease or another diagnosis, such as a rheumatological disease, are at an increased risk for medical complications and mortality from COVID-19. Since inconsistencies persist regarding the use of convalescent plasma (CP), especially in the vulnerable patient population that has received previous treatment with B-cell-depleting monoclonal antibodies, further studies should be performed in thisdirection. The aim of the present study was to describe the characteristics of patients with previous use of B-cell-depleting monoclonal antibodies and describe the potential beneficial effects of CP use in terms of mortality, ICU admission and disease relapse. In this retrospective cohort study, 39 patients with previous use of B-cell-depleting monoclonal antibodies hospitalized in the COVID-19 department of a tertiary hospital in Greece were recorded and evaluated. The mean age was 66.3 years and 51.3% were male. Regarding treatment for COVID-19, remdesivir was used in 89.7%, corticosteroids in 94.9% and CP in 53.8%. In-hospital mortality was 15.4%. Patients who died were more likely to need ICU admission and also had a trend towards a longer hospital stay, even though the last did not reach statistical significance. Patients treated with CP had a lower re-admission rate for COVID-19 after discharge. Further studies should be performed to identify the role of CP in patients with treatment with B-cell-depleting monoclonal antibodies suffering from COVID-19. |
format | Online Article Text |
id | pubmed-10059055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100590552023-03-30 Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates Ioannou, Petros Katsigiannis, Athanasios Papakitsou, Ioanna Kopidakis, Ioannis Makraki, Eirini Milonas, Dimitris Filippatos, Theodosios D. Sourvinos, George Papadogiannaki, Marina Lydaki, Evaggelia Chamilos, Georgios Kofteridis, Diamantis P. Viruses Article Patients receiving treatment with B-cell-depleting monoclonal antibodies, such as anti-CD20 monoclonal antibodies, such as rituximab and obinutuzumab, either for hematological disease or another diagnosis, such as a rheumatological disease, are at an increased risk for medical complications and mortality from COVID-19. Since inconsistencies persist regarding the use of convalescent plasma (CP), especially in the vulnerable patient population that has received previous treatment with B-cell-depleting monoclonal antibodies, further studies should be performed in thisdirection. The aim of the present study was to describe the characteristics of patients with previous use of B-cell-depleting monoclonal antibodies and describe the potential beneficial effects of CP use in terms of mortality, ICU admission and disease relapse. In this retrospective cohort study, 39 patients with previous use of B-cell-depleting monoclonal antibodies hospitalized in the COVID-19 department of a tertiary hospital in Greece were recorded and evaluated. The mean age was 66.3 years and 51.3% were male. Regarding treatment for COVID-19, remdesivir was used in 89.7%, corticosteroids in 94.9% and CP in 53.8%. In-hospital mortality was 15.4%. Patients who died were more likely to need ICU admission and also had a trend towards a longer hospital stay, even though the last did not reach statistical significance. Patients treated with CP had a lower re-admission rate for COVID-19 after discharge. Further studies should be performed to identify the role of CP in patients with treatment with B-cell-depleting monoclonal antibodies suffering from COVID-19. MDPI 2023-03-15 /pmc/articles/PMC10059055/ /pubmed/36992465 http://dx.doi.org/10.3390/v15030756 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ioannou, Petros Katsigiannis, Athanasios Papakitsou, Ioanna Kopidakis, Ioannis Makraki, Eirini Milonas, Dimitris Filippatos, Theodosios D. Sourvinos, George Papadogiannaki, Marina Lydaki, Evaggelia Chamilos, Georgios Kofteridis, Diamantis P. Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates |
title | Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates |
title_full | Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates |
title_fullStr | Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates |
title_full_unstemmed | Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates |
title_short | Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates |
title_sort | convalescent plasma treatment of patients previously treated with b-cell-depleting monoclonal antibodies suffering covid-19 is associated with reduced re-admission rates |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059055/ https://www.ncbi.nlm.nih.gov/pubmed/36992465 http://dx.doi.org/10.3390/v15030756 |
work_keys_str_mv | AT ioannoupetros convalescentplasmatreatmentofpatientspreviouslytreatedwithbcelldepletingmonoclonalantibodiessufferingcovid19isassociatedwithreducedreadmissionrates AT katsigiannisathanasios convalescentplasmatreatmentofpatientspreviouslytreatedwithbcelldepletingmonoclonalantibodiessufferingcovid19isassociatedwithreducedreadmissionrates AT papakitsouioanna convalescentplasmatreatmentofpatientspreviouslytreatedwithbcelldepletingmonoclonalantibodiessufferingcovid19isassociatedwithreducedreadmissionrates AT kopidakisioannis convalescentplasmatreatmentofpatientspreviouslytreatedwithbcelldepletingmonoclonalantibodiessufferingcovid19isassociatedwithreducedreadmissionrates AT makrakieirini convalescentplasmatreatmentofpatientspreviouslytreatedwithbcelldepletingmonoclonalantibodiessufferingcovid19isassociatedwithreducedreadmissionrates AT milonasdimitris convalescentplasmatreatmentofpatientspreviouslytreatedwithbcelldepletingmonoclonalantibodiessufferingcovid19isassociatedwithreducedreadmissionrates AT filippatostheodosiosd convalescentplasmatreatmentofpatientspreviouslytreatedwithbcelldepletingmonoclonalantibodiessufferingcovid19isassociatedwithreducedreadmissionrates AT sourvinosgeorge convalescentplasmatreatmentofpatientspreviouslytreatedwithbcelldepletingmonoclonalantibodiessufferingcovid19isassociatedwithreducedreadmissionrates AT papadogiannakimarina convalescentplasmatreatmentofpatientspreviouslytreatedwithbcelldepletingmonoclonalantibodiessufferingcovid19isassociatedwithreducedreadmissionrates AT lydakievaggelia convalescentplasmatreatmentofpatientspreviouslytreatedwithbcelldepletingmonoclonalantibodiessufferingcovid19isassociatedwithreducedreadmissionrates AT chamilosgeorgios convalescentplasmatreatmentofpatientspreviouslytreatedwithbcelldepletingmonoclonalantibodiessufferingcovid19isassociatedwithreducedreadmissionrates AT kofteridisdiamantisp convalescentplasmatreatmentofpatientspreviouslytreatedwithbcelldepletingmonoclonalantibodiessufferingcovid19isassociatedwithreducedreadmissionrates |